Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Novelli, F.L. Dente, M.L. Bartoli, S. Cianchetti, A. Di Franco, L. Melosini, E. Bacci, P. Paggiaro (Italy). Characterisation of patients with difficult-to-treat and treatment-resistant severe asthma. Eur Respir J 2012; 40: Suppl. 56, 299

Member's Comments

No comment yet.

Related content which might interest you: Management of severe and difficult-to-treat asthma Source: Annual Congress 2013 –Severe asthma: moving from phenotyping to endotyping Year: 2013 Evaluation of the difficult-to-treat severe asthma patient in the clinic Source: Eur Respir Mon 2011; 51: 16-27 Year: 2011 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Severe therapy-resistant asthma Source: International Congress 2016 – PG8 Paediatric asthma Year: 2016 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Characterization of patients with severe COPD Source: International Congress 2018 – COPD around the world Year: 2018 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Diagnosing, treating and preventing severe asthma Source: International Congress 2017 – State of the art session: "Airway diseases" Year: 2017 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019